We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+24.92%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$9.73M
(+8.4%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
177.31%
Top 10 Holdings %
Top 10 Hldgs %
37.67%
Holding
493
New
153
Increased
113
Reduced
67
Closed
127
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$3.82M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$2.47M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$2M |
| 4 |
Ulta Beauty
ULTA
|
+$1.86M |
| 5 |
MON
Monsanto Co
MON
|
+$1.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$7.18M |
| 2 |
Biogen
BIIB
|
+$4.33M |
| 3 |
Cal-Maine
CALM
|
+$3.64M |
| 4 |
Apple
AAPL
|
+$2.74M |
| 5 |
ALR
Alere Inc
ALR
|
+$2.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 39.95% |
| 2 | Consumer Staples | 5.72% |
| 3 | Consumer Discretionary | 5.14% |
| 4 | Technology | 3.35% |
| 5 | Materials | 2.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
CALL
Johnson Controls International
JCI
$85.7B
| $341K | 0.27% |
+69,350
| New | +$3.21M |
|
|
77
Apple
AAPL
$4.9T
| $330K | 0.26% |
11,684
-103,692
| -90% | -$2.74M |
|
|
TBRA
78
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $322K | 0.26% |
+8,106
| New | +$90.4K |
|
79
Eli Lilly
LLY
$1.05T
| $321K | 0.25% |
+4,000
| New | +$320K |
|
|
DVAX
80
PUT
DELISTED
Dynavax Technologies
DVAX
| $320K | 0.25% |
+105,400
| New | +$1.51M |
|
81
CALL
Ionis Pharmaceuticals
IONS
$8.99B
| $315K | 0.25% |
60,000
-115,300
| -66% | -$3.61M |
|
82
PUT
Humana
HUM
$48B
| $294K | 0.23% |
31,900
-26,000
| -45% | -$4.51M |
|
|
MNK
83
PUT
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $292K | 0.23% |
+22,200
| New | +$1.61M |
|
84
Oracle
ORCL
$364B
| $287K | 0.23% |
7,300
+6,300
| +630% | +$257K |
|
|
DVAX
85
DELISTED
Dynavax Technologies
DVAX
| $284K | 0.23% |
+27,030
| New | +$388K |
|
86
PUT
Yum! Brands
YUM
$40.8B
| $283K | 0.22% |
109,194
+70,941
| +185% | +$4.53M |
|
87
Macy's
M
$6.23B
| $278K | 0.22% |
7,500
-5,000
| -40% | -$181K |
|
88
PUT
Gilead Sciences
GILD
$167B
| $270K | 0.21% |
164,000
+9,800
| +6% | +$796K |
|
|
89
PUT
Ulta Beauty
ULTA
$20.6B
| $264K | 0.21% |
18,800
+9,300
| +98% | +$2.35M |
|
90
Salesforce
CRM
$140B
| $257K | 0.2% |
+3,600
| New | +$281K |
|
|
NBIS
91
Nebius Group N.V.
NBIS
$45.1B
| $253K | 0.2% |
12,000
-100
| -0.8% | -$2.17K |
|
92
CALL
Alkermes
ALKS
$8.79B
| $249K | 0.2% |
35,500
| – | – |
|
|
CEMP
93
CALL
DELISTED
Cempra, Inc.
CEMP
| $234K | 0.19% |
+49,600
| New | +$1.07M |
|
94
CALL
Arrowhead Research
ARWR
$10.5B
| $233K | 0.18% |
88,800
+3,000
| +3% | +$19.4K |
|
|
95
CALL
Eli Lilly
LLY
$1.05T
| $231K | 0.18% |
+59,300
| New | +$4.75M |
|
96
uniQure
QURE
$2.77B
| $231K | 0.18% |
+30,158
| New | +$239K |
|
97
CALL
Abbott
ABT
$175B
| $224K | 0.18% |
22,500
+11,000
| +96% | +$471K |
|
98
PUT
Synaptics
SYNA
$4.46B
| $223K | 0.18% |
11,000
-600
| -5% | -$33K |
|
|
99
PUT
iShares Biotechnology ETF
IBB
$9.23B
| $221K | 0.18% |
+45,000
| New | +$4.28M |
|
100
PUT
Teva Pharmaceuticals
TEVA
$37.3B
| $221K | 0.18% |
+60,500
| New | +$3.16M |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q3 2016 Portfolio in Review
As of Q3 2016, FT Options held 493 positions worth $126M, up 8.4% from $116M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $224M of net new capital in Q3 2016, opening 153 new positions and adding to 113 existing holdings. Its largest new stake was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 41% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $2.74M trimmed.
- FT Options's largest Q3 2016 buy was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
- FT Options added most to Procter & Gamble in Q3 2016, an estimated $3.82M increase.
- FT Options's biggest Q3 2016 reduction was Apple, cutting an estimated $2.74M.
- FT Options fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $7.18M.
- FT Options's ten largest holdings make up 38% of its $126M portfolio in Q3 2016.
- FT Options opened 153 new positions and closed 127 in Q3 2016.
- FT Options's portfolio value rose 8.4% quarter-over-quarter to $126M.
Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.